Omeros Corporation

Omeros Corporation is a Seattle-based biopharmaceutical company founded in 1994 that discovers, develops, and commercializes small-molecule and protein therapeutics targeting critical unmet medical needs. The company has built a deep and diverse pipeline of first-in-class assets across orphan and large-market disorders including complement-mediated diseases, addiction, and CNS conditions, leveraging its proprietary GPCR discovery platform and exclusive intellectual property. Omeros is publicly traded on NASDAQ (OMER) and is fully vertically integrated with multiple late- and early-stage assets, including its FDA-approved product YARTEMLEA (narsoplimab) and several clinical-stage programs.